Advice
Following a full submission
enoxaparin (Clexane) is accepted for use within NHS Scotland for the treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI) in conjunction with thrombolytic drugs (fibrin or non-fibrin specific).
In clinical studies using a median of seven days of enoxaparin treatment, enoxaparin demonstrated a reduction in death or non-fatal MI compared to unfractionated heparin.
Download detailed advice85KB (PDF)
Medicine details
- Medicine name:
- enoxaparin (Clexane)
- SMC ID:
- 380/07
- Indication:
- Myocardial infarction with ST-segment elevation (STEMI).
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 July 2009